Depemokimab Reduced Asthma Exacerbations in 2026 Trials
A study found that twice-yearly injections significantly lowered asthma flare-ups in adults with type 2 disease.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Do you trust that less frequent dosing for chronic conditions provides the same health benefits?
In trials conducted in 2026, the injectable drug depemokimab reduced the likelihood of asthma exacerbations by 46 percent over 52 weeks. The treatment offers a potential new maintenance option for patients with uncontrolled type 2 asthma.
Why it matters
Uncontrolled type 2 asthma leads to frequent, unpredictable exacerbations that impact daily quality of life. This therapy provides an alternative treatment path with less frequent dosing compared to current standard maintenance medications.
A pooled analysis of the SWIFT-1 and SWIFT-2 Phase 3 trials evaluated 762 patients who received 100 mg of depemokimab or a placebo. Researchers found a 46 percent reduction in the probability of asthma exacerbations over 52 weeks, with benefits appearing as early as four weeks after the first dose.
The players
National Jewish Health
A leading respiratory research institution where the study's lead author is affiliated.
The details
Depemokimab is designed to target underlying inflammation in patients with type 2 asthma, which is often characterized by high levels of certain immune cells. By administering a 100 mg subcutaneous dose at weeks 0 and 26, the treatment aims to provide sustained clinical control. The trials observed greater efficacy in specific subgroups, including those with an asthma duration of under 10 years and patients with chronic rhinosinusitis with nasal polyps.
Timeline
Week 0: Patients received their first subcutaneous dose of depemokimab or placebo.
Week 4: Researchers observed the first signs of treatment efficacy.
Week 26: Patients received their second dose of treatment.
52 weeks: Total duration for measuring exacerbation rates in the pooled study.
Health Landscape
This development aligns with the ongoing evolution of asthma care toward targeted biologics that reduce the frequency of maintenance treatments. It marks a shift from daily management toward long-acting, injectable options for specific sub-populations defined by type 2 inflammatory markers.
If you struggle with uncontrolled asthma, it is worth discussing with your doctor whether biologic therapies could improve your current treatment plan. Ask your physician if your specific asthma type or history of nasal polyps might make you a candidate for newer maintenance interventions.
The takeaway
The study suggests that twice-yearly dosing of depemokimab may offer a significant reduction in asthma flare-ups for adults with type 2 disease. Keep a detailed log of your exacerbation frequency and symptoms to better inform your next conversation with an allergy or respiratory specialist.
Further reading
Learn more about the latest innovations in Asthma management.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that less frequent dosing for chronic conditions provides the same health benefits?
